SCHEMBL1563671

SCHEMBL1563671

COC(=O)c1sc(-c2ccc(Cl)cc2)cc1NC(N)=O

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.70
KMT2A Q03164 1/20 0.70
KDM4E B2RXH2 6/20 0.69
MAPT P10636 7/20 0.69
TP53 P04637 2/20 0.69
NPC1 O15118 1/20 0.67
CASP3 P42574 1/20 0.67
RAB9A P51151 1/20 0.67
SENP8 Q96LD8 1/20 0.67
SENP7 Q9BQF6 1/20 0.67
SENP6 Q9GZR1 1/20 0.67
IKBKB O14920 5/20 0.64
ALDH1A1 P00352 1/20 0.62
LMNA P02545 1/20 0.62
HPGD P15428 1/20 0.60
HTT P42858 1/20 0.56
ATM Q13315 1/20 0.56
PTPN1 P18031 1/20 0.55
PTPRA P18433 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7057264 0.88 MAPT (0.80) NPSR1KDM4EMAPTTP53IKBKB
SCHEMBL7054758 0.87 KDM4E (0.70) NPSR1KMT2AKDM4EMAPTTP53
SCHEMBL1382530 0.86 IKBKB (0.78) NPSR1KMT2AKDM4EMAPTNPC1
SCHEMBL3076668 0.85 PTPN1 (0.75) NPSR1KMT2AKDM4EMAPTTP53
SCHEMBL24131393 0.84 NPSR1 (0.77) NPSR1KMT2AKDM4EMAPTTP53
SCHEMBL4979550 0.83 NPSR1 (0.65) NPSR1KMT2AKDM4EMAPTTP53
SCHEMBL2157661 0.83 HPGD (0.84) NPSR1KMT2AKDM4EMAPTTP53
SCHEMBL4147698 0.82 MAPT (0.67) NPSR1KMT2AKDM4EMAPTTP53
SCHEMBL1406017 0.81 POLB (0.71) KDM4EMAPTTP53IKBKBALDH1A1
SCHEMBL1563005 0.81 MAPT (0.64) NPSR1KMT2AKDM4EMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305671-A1 Thiophene and thiazole derivatives as CHK1 inhibitors AstraZeneca AB (SE) 2011-04-06 EP disclosed
CN-100584840-C Substituted heterocyclic compounds and uses thereof ASTRAZENECA AB 2010-01-27 CN disclosed
CN-1922172-A Substituted heterocyclic compounds and uses thereof ASTRAZENECA AB (SE) 2007-02-28 CN disclosed
US-20070010556-A1 Thiophene derivatives as chk 1 inhibitors ASTRAZENECA AB (SE) 2007-01-11 US disclosed
EP-1732920-A2 THIOPHENE DERIVATIVES AS CHK 1 INHIBITORS AstraZeneca AB (SE) 2006-12-20 EP disclosed
WO-2005066163-A2 THIOPHENE DERIVATIVES AS CHK 1 INIHIBITORS ASTRAZENECA AB (SE) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010556-A1 Thiophene derivatives as chk 1 inhibitors CHEK1, CHKA, CHEK2 NPSR1 4861/4885KMT2A 2078/4885KDM4E 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.